Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
NCT00499733
Terminated
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with cryoablation may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with cryoablation works in treating patients with advanced or metastatic epithelial cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/16/2019
Locations: Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Cancer
Register for Updates
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
NCT00004464
Completed
OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia. II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide shortens the time to recovery in these patients. III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal hemoglobinuria.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
01/16/2019
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal
Register for Updates
Preoperative Herceptin and Navelbine for Breast Cancer
NCT00148681
Completed
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2019
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Register for Updates
Cyclophosphamide and Alemtuzumab In Lymphoma
NCT03132584
Terminated
This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/10/2019
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Register for Updates
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
NCT00877110
Completed
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8. The NK cells must come from a family member who shares half of the HLA proteins which are immune proteins important in transplant. NK cells are a type of white blood cell. They can recognize and kill abnormal cells in the body and can work together with antibodies to kill target cells. The antibody 3F8 specifically recognize... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/09/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Register for Updates
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
NCT01416974
Completed
The purpose of this Phase I study is to test the safety and effect of specially prepared cells collected from the patients called "modified T cells." We want to find a safe dose of modified T cells for patients who have disease remaining after initial chemotherapy. We also want to find out what effects these T cells have on you and your leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Leukemia
Register for Updates
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
NCT01457131
Terminated
Background: - A new cancer treatment involves collecting white blood cells from an individual, modifying them to secrete IL-2 and target the ESO-1 protein expressed on some cancers, and returning them to the body. The cells may then be able to seek out the cancer cells and destroy them. Some kinds of cancer contain a protein called ESO-1, which is found on the surface of the cells. Doctors want to modify white blood cells to have an anti-ESO-1 effect, and use them to treat the cancer that has t... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/05/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
Register for Updates
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
NCT00513292
Completed
This randomized phase III trial is studying giving fluorouracil together with epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab to see how well it works compared with giving paclitaxel together with trastuzumab followed by fluorouracil, epirubicin, cyclophosphamide, and trastuzumab in treating women with palpable breast cancer that can be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2019
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama +114 locations
Conditions: HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
NCT02208037
Completed
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free survival at one year after transplant compared to the current standard prophylaxis regimen.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/02/2019
Locations: City of Hope National Medical Center, Duarte, California +29 locations
Conditions: Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Register for Updates
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
NCT00074490
Terminated
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling. However, severe problems may follow these transplants because of the high-dose chemotherapy and radiation that accompany the procedure. Also, donated immune cells sometimes attack healthy tissues in a reaction called graft-versus-host disease (GVHD), damaging organs such as the liver, intestines and skin. To reduce toxicity of high-dose preparati... Read More
Gender:
ALL
Ages:
Between 11 years and 90 years
Trial Updated:
12/28/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland +1 locations
Conditions: Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Register for Updates
Metronomic Therapy in Patients With Metastatic Melanoma
NCT01542255
Terminated
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible. All patients will be treated as outlined below with combined vinblastine, cyclophosphamide, and dacarbazine. Patients will be treated continuously, until evidence of progression of disease, or for up to two cycles following disappearance of all disease. A cycle will be defined as three weeks of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2018
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Metastatic Melanoma
Register for Updates
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
NCT00774202
Completed
This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of Rituxan. Patients eligible for this protocol will be stratified into two subgroups according to their initial response to Rituxan.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
12/21/2018
Locations: 525 East 68th Street, New York, New York
Conditions: Immune Thrombocytopenic Purpura
Register for Updates